Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

F. Peyvandi, M. Scully, J. A. Kremer Hovinga, P. Knöbl, S. Cataland, K. De Beuf, F. Callewaert, H. De Winter, R. K. Zeldin

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

Medicine & Life Sciences